Almirall maintains upwards trajectory

11 November 2019

Spanish drugmaker Almirall (ALM: MC) has sustained the growth with its most recent financial results that has characterized the company’s turnaround since 2017.

The dermatology firm has presented results for the year-to-date for 2019, ending at September 30, and total revenue is recorded at 683.2 million ($754 million), a 17% jump on the first nine months of 2018.

Earnings before interest, taxes, depreciation and amortization (EBITDA) were up 58%, at 236.5 million euros, and Almirall confirmed its previous guidance for 2019 as a whole of low double-digit revenue growth and EBITDA of 300 to 310 million euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK